Toronto, ON (Press Release) – Telo Genomics Corp. (TSX-V: TELO) (the “Com­pany” or “TELO”), is pleased to announce that it has signed a col­lab­o­ration agree­ment with Mayo Clinic in Minnesota to conduct clin­i­cal studies to eval­u­ate and val­i­date the utility of the Com­pany’s pro­pri­e­tary telomere analytics as a prog­nos­tic solu­tion for Multiple Myeloma.

The col­lab­o­ration studies will be led by Dr. Shaji Kumar, MD, and were designed to in­clude two retro­spec­tive­ phases with the poten­tial of a third pro­spec­tive­ phase. For each phase, TELO’s analytics will be employed to: 1) predict the pro­gres­sion of multiple myeloma precursors to full stage multiple myeloma, and 2) predict patient re­sponse­s to first-line ther­apy at the point of diag­nosis.

Multiple Myeloma (“MM”) is a highly chal­leng­ing blood cancer that forms in plasma cells, a type of white blood cell with an annual in­ci­dence rate of approx­i­mately 32,000 newly diag­nosed cases in North America and approx­i­mately 40,000 newly diag­nosed cases in Europe. MM is cur­rently incurable but patients may go into remission with treat­ment. MM is preceded by an asymp­tomatic ex­pan­sion of plasma cells, recog­nized as mono­clonal gam­mop­athy of undetermined sig­nif­i­cance (“MGUS”) or smol­der­ing MM (“SMM”). Patients with MGUS or SMM are generally not treated but monitored reg­u­larly to capture the onset of full stage MM if the patient progresses. Once patients are diag­nosed with full stage MM they may be treated with several avail­able treat­ment regi­mens; how­ever, it is esti­mated that 20% of the patients will relapse on first line treat­ment within 12-15 months. Predicting patient pro­gres­sion from MGUS or SMM to full stage myeloma, and predicting patient re­sponse­ to first line ther­apy remain critical unmet needs in the clinic.

“Telo Genomics tech­nology has shown promising results in several academic studies focused on blood cancers in­clud­ing Multiple Myeloma,” commented Dr. Kenneth Anderson, Dana-Farber Cancer Institute, and member of TELO’s Clinical and Scientific Advisory Board.

Phase 1 of the studies is ex­pec­ted to be launched within the first quarter of 2020.

“We are ex­cited to work with Dr. Kumar," said Sherif Louis, CEO of Telo Genomics. “TELO’s board of directors has identified Multiple Myeloma as a priority ini­tia­tive for the Com­pany’s clin­i­cal pro­grams, these studies are foundational to ad­vance TELO-MM tests to­wards com­mer­cial­iza­tion.”

About Telo Genomics

Telo Genomics (TELO) is a world leader in the quantitative analysis of telomeres, with a particular focus on liquid biopsy diagnostics and prog­nos­tics. Its pro­pri­e­tary plat­form tech­nology has the poten­tial to be a powerful health­care tool to im­prove the diag­nosis and treat­ment of several cancers and neurological dis­eases. TELO employs a pro­pri­e­tary software plat­form, TeloView®, to precisely quantify specific features of patient’s telomeres in three dimensions. This tech­nology has been suc­cess­ful in detecting early dis­ease, determining the aggressiveness and pro­gres­sion of dis­ease and providing powerful insights to guide ther­apy and treat­ment protocols, all of which should con­trib­ute to im­proved clin­i­cal out­comes for patients. TELO benefits from over 20 years of foundational and trans­la­tional academic re­search conducted by the Com­pany’s founder providing a wealth of more than 150 peer reviewed publications, 25 clin­i­cal studies involving more than 3,000 patients and 20 dif­fer­en­t cancers and Alzheimer’s dis­ease.

Neither the TSX Venture Ex­change nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Ex­change) ac­cepts re­spon­si­bil­ity­ for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain in­for­ma­tion con­tained herein may con­sti­tute “forward-looking in­for­ma­tion” under Canadian se­cu­ri­ties legislation. Generally, for­ward-looking in­for­ma­tion can be identified by the use of for­ward-looking terminology such as “will”, or variations of such words and phrases or state­ments that cer­tain actions, events or results “will” occur. Forward-looking state­ments re­gard­ing the con­sol­i­da­tion, the offering, the use of proceeds are based on the Com­pany’s esti­mates and are subject to known and unknown risks, un­cer­tainties and other factors that may cause the actual results, level of activity, per­for­mance or achieve­ments of the Com­pany to be ma­teri­ally dif­fer­en­t from those ex­pressed or implied by such for­ward-looking state­ments or for­ward-looking in­for­ma­tion, in­clud­ing capital ex­pen­di­tures and other costs. There can be no assurance that such state­ments will prove to be accurate, as actual results and future events could differ ma­teri­ally from those antic­i­pated in such state­ments. Accord­ingly, readers should not place undue reliance on for­ward- looking state­ments and for­ward-looking in­for­ma­tion. The Com­pany will not update any for­ward-looking state­ments or for­ward-looking in­for­ma­tion that are in­cor­po­rated by reference herein, except as required by appli­cable se­cu­ri­ties laws.

Source: Telo Genomics.